logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

 


Investing as Shakespearean Tragedy: The Story of Ariad Pharmaceutical (ARIA)

By  +Follow November 12, 2013 8:57AM
Share:
Tickers Mentioned:

Shares in Ariad Pharmaceuticals (ARIA) were up 10.78 percent on Veterans Day. Even for a small-cap like Ariad, coming in at a valuation just under a half billion dollars, that’s normally what one would consider a pretty solid bounce. That’s a day that, for a lot of investors, would stand out. However, for the battered shareholders of Ariad, it probably doesn’t even register any more. Okay, that’s not true, double-digit jumps always register. But after the Odyssey Ariad’s been on for the last month, it’s not difficult to imagine that days like Monday just get lost in the shuffle.

It’s not often you see a company go on a ride like Ariad just has, plunging sharply, appearing to rally, rinse and repeat. And it’s a drama that’s swept a lot of people up. Over the last 3 months, Ariad’s moved an average of 11.14 million shares a day, good to make it the 75th most traded security over that period, one spot behind Elon Musk’s Tesla Motors (TSLA) , a battleground stock and the source of general market fascination. That’s a class that contains mostly mega-cap blue chips and high-profile ETFS, relatively few small-cap companies. And that’s not even the whole story. Ariad’s heavy volume is drawn mostly from the massive spike this last month. Over the last 30 days Aria has been moving an average of 20 million shares a day, meaning that more than 10 percent of outstanding shares are trading hands on an average day.

So what’s happening with this company? The story’s a simple one, but, for Ariad investors, it’s a tragic one.

Volatile Month

Lets start with the whole story: since the start of October, Ariad Pharmaceutical’s stock has lost over 85 percent of its value. No matter how specifically you pull things apart, that’s the simple fact one cannot avoid. Especially if you’ve owned Ariad for that whole stretch. But inside that one big sell-off is a series of daily price moves that could drive an investor insane. Here’s a timeline or the events that have brought Ariad so much grief:

October 8:

After market close, news gets out regarding the clinical trials for Ariad’s leukemia drug Iclusig and it’s bad. In fact, if you’re long Ariad, it’s positively awful. The drug showed blood clots developing in 11.8 percent of people treated with Iclusig after 24 months. This was a big jump from the 8 percent rate found after 11 months, and it prompts the FDA to block Ariad from enrolling any new patients to drug trials for Iclusig.

Like most small-cap pharma companies, Ariad’s future is tied mainly to just a couple of drugs, and the news that one of them might not be safe is pretty drastic. Especially when one considers that the nearly 800 percent gains from the start of 2010 to October 7 had a lot to do with the fact that Iclusig looked so promising, even getting accelerated approval based on its Phase 2 clinical data.

So it shouldn’t be surprising that the market’s reaction was swift and vengeful. As soon as investors got a crack at selling their position on October 9 shares plummeted over 65 percent.

October 10-18:

If the story ended there, it would be pretty much in line with a familiar narrative: small-cap pharma plummets on negative results of clinical trial. But, while nothing matched the degree of the move on the ninth, Ariad kept trading at heavy volumes and kept posting double-digit moves.

A series of analyst downgrades hit the company on October 10, with Barclays (BCS) downgrading the stock from overweight to underweight and cutting the price target from $25 a share to $4 (ouch). The stock kept falling, losing another 30 percent from October 10-16 but coasting into what appeared to be a bottom on October 16.

Then, on October 17, signs of life! Following comments from JP Morgan (JPM) analyst Cory Kasimov that physicians may not be all that concerned about the blood clots, the stock rebounded, posting a 10.78 percent gain and potentially giving hope to Ariad owners that the worst was behind them.

Except that it wasn’t. Not at all. October 18, word came out that Ariad and the FDA had agreed to halt testing of Iclusig entirely based on the rate of blood clotting incidences. The discontinuation of the late-stage trial dubbed Epic by Ariad caused shares to plunge more than 40 percent that day.

October 21-October 30:

After any stock gets hammered that hard in that short a period, one might expect it to bounce back. At least a little. Considering how steep the discount it’s trading at as compared to a mere two weeks ago, it has to garner at least a little interest, right?

And it did. The company staged a pretty substantial rally, gaining almost 50 percent in just nine days. It’s not much when one considers just how fall the stock fell prior to the rally, but at least the battered shareholders got a respite in the end, right?

October 31:

Only it wasn’t the end. Halloween was extra spooky if you had decided to wait out Ariad’s steep decline. Ariad announced that it would suspend marketing and distribution of Iclusig while it "continues to negotiate updates to the U.S. prescribing information." In retrospect, it certainly seems as though this shouldn’t have been all that surprised, but it clearly surprised at least some people as the company’s stock plunged nearly 45 percent.

And Beyond…?

Where Ariad’s going from here is unclear. Since the start of November, the stock’s up over 15 percent, including a 17.27 percent leap the day after Halloween and Monday’s double-digit gain. However, precisely what to expect moving forward is unclear. In the event that Ariad can return Iclusig to the market and ensure that it’s safe, there’s a pretty good chance the stock takes off. That said, there’s no real way to know whether or not that’s possible. In the meantime, the company announced that it was shedding 40 percent of its American-based workforce on November 7.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Liked What You Read? Join Equities.com and Connect With Your Favorite Financial Experts FOR FREE! Members of Equities.com gain access to our leading financial news and content, active social investment community, proprietary research tools including the 2014 Small-Cap Stars, E.V.A. reports and more.

Results for ARIA
Lecorb
2 Sep 15 09:52:44
Midday Gainers / Losers http://t.co/L4AJYu1aQC $SURG, $WPCS, $VRA, $OFG, $UNIS, $AXPW, $RSO, $DTSI, $EFOI, $MBI, $SFXE, $CDRB, $ARIA, $HTWR,
scott
2 Sep 15 09:47:55
$aria is dead
ed hammond
2 Sep 15 09:35:34
RT @BloombergDeals: Baxalta said to abandon takeover talks with Ariad $BXLT $ARIA http://t.co/geeqLnJhGG @EdHammondNY @ManuBaigorri
Adam Feuerstein
2 Sep 15 09:33:06
The “Karen knows Anna” takeover thesis needs re-working, @BosBizDon. $ARIA
Zacks.com
2 Sep 15 09:32:33
In our Biotech roundup we discuss the possibility of ARIAD being a takeover target. $ARIA $GILD $CELG $BIIB $FOLD http://t.co/mjyEJkoUFb
knewsapp
2 Sep 15 09:24:46
Baxalta Reportedly Abandons Takeover Talks With Ariad Pharma| http://t.co/RZQ0xT88qN| $SHPG $SHPGF $ARIA $BXLT #knewsapp
Rosner Stocks
2 Sep 15 09:24:08
$ARIA Short Sales Updated Wednesday, September 2, 2015 11:59:37 AM $XGTI $GE $SCO $TSO http://t.co/w0SCyBV7fr
The Fly
2 Sep 15 09:22:36
On The Fly: Top stock stories at midday $GPRO $AMBA $HRB $VRA $ARIA $BXLT $HTWR: Full Story http://t.co/SIJtcxhcv4
Charlie Weeks, PE
2 Sep 15 09:22:19
Indicator (Envelopes) signaled a Buy for $ARIA at $7.44 #stockmarket- http://t.co/mG5DNHov4t http://t.co/gqlJcuWgu2
Global BD Trading
2 Sep 15 09:18:34
Some stocks We are trading today: $ARIA $OFG $TSRO $QIWI
Egor Romanyuk
2 Sep 15 09:14:40
@markeiy they are Now $ARIA @Cash_Flow
DeltaRho
2 Sep 15 09:09:31
RT @blsuth: ICYMI: $BXLT said to abandon talks to buy $ARIA. Scoop from @EdHammondNY and @ManuBaigorri: http://t.co/bUW5D2cpMH @BloombergDe…
CoNimby Fund
2 Sep 15 09:07:57
RT @valuewalk: Baxalta Inc Set To Abandon Talks With Ariad Pharmaceuticals, Inc. http://t.co/pSSUG5LpBE $BXLT $ARIA http://t.co/zdRVcRM3NQ
Frances Horodelski
2 Sep 15 09:07:45
RT @valuewalk: Baxalta Inc Set To Abandon Talks With Ariad Pharmaceuticals, Inc. http://t.co/pSSUG5LpBE $BXLT $ARIA http://t.co/zdRVcRM3NQ
ValueWalk
2 Sep 15 09:07:07
Baxalta Inc Set To Abandon Talks With Ariad Pharmaceuticals, Inc. http://t.co/pSSUG5LpBE $BXLT $ARIA http://t.co/zdRVcRM3NQ
Brooke Sutherland
2 Sep 15 09:07:04
ICYMI: $BXLT said to abandon talks to buy $ARIA. Scoop from @EdHammondNY and @ManuBaigorri: http://t.co/bUW5D2cpMH @BloombergDeals
Stock Wars
2 Sep 15 09:00:01
U.S. Losers: $ARIA -17.21%, $HTWR -16.91%, $AMBA -15.06%, $NAV-D -10.68%, $GPRO -9.7% http://t.co/jdoP0QgKi5 #StockWars
[SMART MONEY]
2 Sep 15 08:40:49
441K BID @ 7.47 AND STILL NOT MOVING= HUH?? ARIA $ARIA http://t.co/t4fQseGlD3
ThePacer
2 Sep 15 08:38:26
Good morning in @IU_Chat $NFLX $TVIX wins & papercut on $ARIA. +0.73% advance today, +3%~ portfolio growth since Aug. http://t.co/F7YbDW4SbT
Jason Knapp
2 Sep 15 08:36:35
I thought that it was wise to sell on the $ARIA rumor. Baxalta Said to Abandon Takeover Talks With Drugmaker Ariad http://t.co/d3k87hUkjr
Hariharan Vaidyanath
2 Sep 15 08:29:31
RT @DrSManian: No $ARIA Maybe $IMGN $HALO ?? https://t.co/byvRdbmf6d
Quantcha
2 Sep 15 08:25:55
Big Loser Alert: Trading today’s -18.5% move in ARIAD PHARMACEUTICALS $ARIA http://t.co/xgghOShcVs
PolgarStocks
2 Sep 15 08:25:13
$ARIA Stock Price Updated Wednesday, September 2, 2015 11:08:29 AM $DBA $INTC $UGAZ $GDX http://t.co/VKgVZHXuVl
Nara
2 Sep 15 08:24:52
$KND $BCRX $ARIA $CVM $ETRM $CPHD JBEM Glioblastoma Data Trade. Read full DD here: https://t.co/gv9He7HRvh
The GMP Group
2 Sep 15 08:24:06
RT @fwpharma: Baxalta ends takeover talks with Ariad due to price: report http://t.co/DqwvBi77KJ $BXLT $ARIA #pharma
Kristina Duering
2 Sep 15 08:21:11
RT @DrSManian: No $ARIA Maybe $IMGN $HALO ?? https://t.co/byvRdbmf6d
FirstWord Pharma
2 Sep 15 08:20:31
Baxalta ends takeover talks with Ariad due to price: report http://t.co/DqwvBi77KJ $BXLT $ARIA #pharma
Andrea Magri
2 Sep 15 08:20:13
RT @DrSManian: No $ARIA Maybe $IMGN $HALO ?? https://t.co/byvRdbmf6d
Tarun Jindal
2 Sep 15 08:17:56
RT @DNev47: Ariad Declines Baxalta Offer; Gilead Short Interest Up - http://t.co/lRFykpiTOP $ARIA
PharmaCompass
2 Sep 15 08:17:52
RT @DNev47: Ariad Declines Baxalta Offer; Gilead Short Interest Up - http://t.co/lRFykpiTOP $ARIA
Donald J Olive
2 Sep 15 08:17:48
RT @theflynews: ARIAD takeover negotiations with Baxalta break down over price. The details: http://t.co/XBDBxozvbi $ARIA $BXLT
HotStockMarket
2 Sep 15 08:16:04
Heading into the lunch hour, here are the most active discussions: $DWTI $AMBA $NFLX $OPK $TSRO $HRB $WMGI $ARIA http://t.co/8UEZYVJo0z
S Manian
2 Sep 15 08:16:02
No $ARIA Maybe $IMGN $HALO ?? https://t.co/byvRdbmf6d
nobullshytrading
2 Sep 15 07:59:15
$ARIA ROFL
NKaz
2 Sep 15 07:58:46
$ARIA slow and steady
ChimeraResearchGroup
2 Sep 15 07:54:29
September 2 Biotech Update $adap $ARIA $bxlt $INCY $juno https://t.co/kUnTm9GQry
CorporateTransaction
2 Sep 15 07:54:21
RT BloombergDeals: Baxalta said to abandon takeover talks with Ariad $BXLT $ARIA http://t.co/kk8X8pgEwl EdHammondNY ManuBaigorri
NKaz
2 Sep 15 07:52:21
Covered $ARIA for 1k+ profit @SykesStudents @timothysykes
Kristyn Hyland
2 Sep 15 07:51:06
RT @BloombergDeals: Baxalta said to abandon takeover talks with Ariad $BXLT $ARIA http://t.co/geeqLnJhGG @EdHammondNY @ManuBaigorri
King Buffett
2 Sep 15 07:50:58
RT @BloombergDeals: Baxalta said to abandon takeover talks with Ariad $BXLT $ARIA http://t.co/geeqLnJhGG @EdHammondNY @ManuBaigorri
Lizzie Fournier
2 Sep 15 07:50:24
Baxalta said to abandon takeover talks with Ariad $BXLT $ARIA http://t.co/BPIQzKTYdp @EdHammondNY @ManuBaigorri
Bloomberg Deals
2 Sep 15 07:50:24
Baxalta said to abandon takeover talks with Ariad $BXLT $ARIA http://t.co/geeqLnJhGG @EdHammondNY @ManuBaigorri
leahanne
2 Sep 15 07:50:19
Volume Alert - ARIA 7.49 Ariad Pharmaceuticals $ARIA Hit a high today of 7.68 Closing the day 10:30 at 7.49 -1 http://t.co/tSxJcHMUSI
docnuman
2 Sep 15 07:49:55
RT @theflynews: ARIAD takeover negotiations with Baxalta break down over price. The details: http://t.co/XBDBxozvbi $ARIA $BXLT
The Fly
2 Sep 15 07:49:02
ARIAD takeover negotiations with Baxalta break down over price. The details: http://t.co/XBDBxozvbi $ARIA $BXLT
JJ
2 Sep 15 07:47:42
$aria good time to get in on the cheap if you missed the last bounce, everything still rumors nothing confirmed
Zacks.com
2 Sep 15 07:46:53
In our Biotech stock roundup we breakdown recent news by Amgen. $AMGN $ARIA $CELG $BIIB $FOLD http://t.co/7fsUmQUvZt
JJ
2 Sep 15 07:45:47
@hieuvnguyen $aria right now it's all rumors and neither company has confirmed a walking away, activist investors that will push for sale
i_like_bb_stock
2 Sep 15 07:45:07
$ARIA back in the shit buyout rumors virtually never come true
US_proptrader
2 Sep 15 07:44:27
$ARIA $HLX $TRVN autocharts @ http://t.co/f6cpQoVS67
				
				
By  +Follow November 12, 2013 8:57AM
Share:

Comments

 

blog comments powered by Disqus

 Today's Must Reads

Welcome to Equities.com's Small-Cap Throwdown


These Analysts Called Apple's (AAPL) Collapse, Here's What They're Saying Now

7 Dow Stocks Worth Owning and a Lot that Aren't

Sprint Turnaround Has Begun


Saving the

Small-Cap Market

 

Small-cap stocks offer investors many benefits, ranging from higher growth potential to overlooked value opportuni... in Equities.com's Hangs on LockerDome

About us

Equities.com is an advanced financial data portal and social network designed to connect self-directed investors with the world’s most innovative startup and small cap companies. Through our in-depth coverage of small cap markets, comprehensive research and stock valuation reports, state of the art issuer products, and world class events, Equities.com provides the social tools and insight that drive tomorrow’s investment relationships and opportunities.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.

Login or Register

LOG IN